Certara, Inc.
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation s…
Medical - Healthcare Information Services
US, Princeton [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 24.75 | 3.26 | 2.62 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -17.61 | 4.85 | 5.89 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 0.66 | 6.61 | 6.57 | |
| Cash | -4.07 | 1.44 | 1.50 | |
| Capex | 18.15 | -0.02 | -0.03 | |
| Free Cash Flow | -96.21 | < 0.005 | 0.12 | |
| Revenue | 9.76 | 0.61 | 0.55 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | -3.41 | 0.46 | 0.48 | |
| Operating Margin | -89.35 | < 0.005 | -0.05 | |
| ROA | 61.90 | < 0.005 | < 0.005 | |
| ROE | 62.67 | < 0.005 | -0.01 | |
| ROIC | -90.07 | < 0.005 | < 0.005 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of CERT is permitted for members.
5
Growth
The "Growth Entry" for the Focus of CERT is permitted for members.
6
Leverage & Liquidity